Recent Progress and Pitfalls in Testing Novel Agents in Castration-Resistant Prostate Cancer

European Urology

Volumn 56, Issue 4, 2009, Pages 606-608

  Bellmunt, Joaquim ^a,b   Rosenberg, Jonathan E ^b   Choueiri, Toni K ^b  

^a HOSPITAL DEL MAR   (Spain)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; BEVACIZUMAB; CALCITRIOL; CNTO 328; DOCETAXEL; EPOTHILONE A; EPOTHILONE B; ESTRAMUSTINE; INTERLEUKIN 6 ANTIBODY; IXABEPILONE; LENALIDOMIDE; LEXIDRONAM SAMARIUM SM 153; MDV 3100; MITOXANTRONE; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC; PROVENGE; SATRAPLATIN; SORAFENIB; TAXANE DERIVATIVE; TRABECTEDIN; UNCLASSIFIED DRUG; VIRUS VACCINE; XRP 6258;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DRUG SCREENING; EDITORIAL; FOWLPOX VIRUS; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; VACCINIA;

ANDROGEN ANTAGONISTS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 69349101825     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.07.015     Document Type: Editorial

References (15)

1. Chi K.N., Bjartell A., Dearnaley D., et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 56 (2009) 594-605
2. Hussain M., Goldman B., Tangen C., et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27 (2009) 2450-2456
3. Wu S, Posadas E, Scripture C, et al. BAY 43-9006 (sorafenib) can lead to improvement of bone lesions in metastatic androgen-independent prostate cancer despite rises in serum PSA levels. In: Proceedings from the American Society of Clinical Oncology 2006 Prostate Cancer Symposium; February 24-26, 2006; San Francisco, CA. Abstract 259.
4. Chi K.N., Ellard S.L., Hotte S.J., et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19 (2008) 746-751
5. Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 25 (2007) 669-674
6. Small E.J., Schellhammer P.F., Higano C.S., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 (2006) 3089-3094
7. Kantoff P.W. Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 27 Suppl (2009) abstract 5013
8. Wang X., Yu J., Sreekumar A., et al. Autoantibody signatures in prostate cancer. N Engl J Med 353 (2005) 1224-1235
9. Tran C., Ouk S., Clegg N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 (2009) 787-790
10. Tomlins S.A., Rhodes D.R., Perner S., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
11. Attard G., Swennenhuis J.F., Olmos D., et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69 (2009) 2912-2918
12. Morris M.J., Pandit-Taskar N., Carrasquillo J., et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27 (2009) 2436-2442
13. Fizazi K., Beuzeboc P., Lumbroso J., et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27 (2009) 2429-2435
14. Sternberg C.N., Petrylak D.P., Witjes F., et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC. Results of a randomized phase III trial. J Clin Oncol 25 Suppl (2007) abstract 5019
15. Rosenberg J.E., Ryan C.J., Weinberg V.K., et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 27 (2009) 2772-2778